利妥昔单抗治疗非霍奇金淋巴瘤9例

Effect of Rituximab on Non-Hodgkin Lymphoma: A Report of 9 Cases

[目的]观察利妥昔单抗治疗非霍奇金淋巴瘤的疗效和毒性反应。[方法]9例均为住院患者,用药剂量为375mg/m2,每周1次,连续4～6次,可与化疗方案联用。[结果]CR5例,PR1例,SD1例,PD2例,总有效率(RR)为66.67%,其中ⅠA期6例,ⅢB期1例,ⅣB期2例。主要毒副反应为发热、寒战、胸闷、一过性皮疹及短暂的肝功能指标升高等。[结论]利妥昔单抗联合化疗是治疗低度恶性非霍奇金淋巴瘤有效而安全的方案。

To investigate the response and toxicity of rituximab in the treatment for Non-Hodgkin lymphoma. Nine cases of inpatient received rituximab 375mg/m2 once a week, four to six times combined with chemotherapy (8 cases). Five cases were complete remission and one showed partial remission. The overall response rate was 66.67%. The major toxicities were fever, chill, tire, tetter, transitory abnormal liver function and so on. [Conclusion] Rituximab is effective for patients with low-malignant non-Hodgkin lymphomas.